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Aims The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart
failure with reduced ejection fraction (HFrEF) is being tested in the Global Approach to Lowering Adverse Cardiac
outcomes Through Improving Contractility in Heart Failure (GALACTIC-HF) trial. Here we describe the baseline
characteristics of participants in GALACTIC-HF and how these compare with other contemporary trials.
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Methods and
results
Adults with established HFrEF, New York Heart Association (NYHA) functional class ≥II, ejection fraction ≤35%, ele-
vated natriuretic peptides and either current hospitalization for heart failure or history of hospitalization/emergency
department visit for heart failure within a year were randomized to either placebo or omecamtiv mecarbil
(pharmacokinetic-guided dosing: 25, 37.5, or 50 mg bid). A total of 8256 patients [male (79%), non-white (22%),
mean age 65 years] were enrolled with a mean ejection fraction 27%, ischaemic aetiology in 54%, NYHA class II 53%
and III/IV 47%, and median N-terminal pro-B-type natriuretic peptide 1971 pg/mL. Heart failure therapies at baseline
were among the most effectively employed in contemporary heart failure trials. GALACTIC-HF randomized patients
representative of recent heart failure registries and trials with substantial numbers of patients also having characteris-
tics understudied in previous trials including more from North America (n = 1386), enrolled as inpatients (n = 2084),
systolic blood pressure <100 mmHg (n = 1127), estimated glomerular filtration rate <30 mL/min/1.73 m2 (n = 528),
and treated with sacubitril/valsartan at baseline (n = 1594).
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Conclusions GALACTIC-HF enrolled a well-treated, high-risk population from both inpatient and outpatient settings, which will
provide a definitive evaluation of the efficacy and safety of this novel therapy, as well as informing its potential future
implementation.
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Keywords Heart failure • Omecamtiv mecarbil • Cardiac myosin activator • Inotrope • Myotrope •
Cardiovascular outcomes trial
Introduction
The pathogenesis of heart failure with reduced ejection fraction
(HFrEF) is characterized primarily by a decrease in systolic function
independent of the specific aetiology. Contemporary therapies do
not directly address this fundamental defect, but rather act on the
compensatory pathways that are stimulated by this loss of function.
Omecamtiv mecarbil1 is a cardiac myosin activator2 and the first of
a novel class of myotropes,3 agents that directly improve myocar-
dial function by selectively increasing cardiac sarcomere function.
Clinical studies in healthy volunteers4 and patients with stable
chronic5 and acute heart failure6 show that omecamtiv mecarbil
improves cardiac performance. In the COSMIC-HF study,7 patients
with chronic HFrEF treated with omecamtiv mecarbil for 20 weeks
had improved systolic function and structure demonstrated by
increased systolic ejection time,8–10 fractional shortening, ejection
fraction and stroke volume as well as decreased left ventricu-
lar systolic dimensions and volumes. Omecamtiv mecarbil treat-
ment also led to reductions in N-terminal pro-B-type natriuretic
peptide (NT-proBNP) and heart rate, consistent with decreased
ventricular stress and less neurohormonal activation. Importantly,
the significant reductions in left ventricular diastolic and systolic
dimensions and volumes were suggestive of beneficial reverse
ventricular remodelling. These findings suggest that omecamtiv
mecarbil might reduce both heart failure hospitalizations11 and
mortality.12
The Global Approach to Lowering Adverse Cardiac outcomes
Through Improving Contractility in Heart Failure (GALACTIC-HF)
trial is the first to examine whether selectively increasing cardiac












































. outcomes.13 Due to the absence of adverse effects on blood pres-
sure, heart rate, renal function or potassium homeostasis with
omecamtiv mecarbil, GALACTIC-HF enrolled a broad range of
patients from both the inpatient and outpatient settings, many
of whom have been specifically excluded in other contemporary
heart failure trials. GALACTIC-HF tests the hypotheses that ome-
camtiv mecarbil can safely improve symptoms, prevent clinical
heart failure events, and delay cardiovascular death in patients with
HFrEF.
Methods
The GALACTIC-HF (ClinicalTrials.gov NCT02929329; EU Clinical
Trials Register 2016-002299-28) trial is a multicentre, random-
ized, double-blind, placebo-controlled, event-driven cardiovascular
outcomes trial to evaluate the efficacy, safety and tolerability of
omecamtiv mecarbil in patients with chronic HFrEF.13
Summary of GALACTIC-HF design
People aged 18–85 years with a history of symptomatic [New York
Heart Association (NYHA) functional class II–IV] HFrEF (ejection frac-
tion≤ 35%), optimally treated with standard of care pharmacologic and
device therapy for HFrEF were eligible. Participants were currently hos-
pitalized for heart failure (inpatients; approximately 25% of enrolment)
or within 1 year had either an urgent visit to the emergency depart-
ment for heart failure or a hospitalization for heart failure (outpatients).
In addition, patients had NT-proBNP concentration ≥400 pg/mL or
B-type natriuretic peptide (BNP) ≥125 pg/mL at screening (if in atrial
fibrillation/flutter: NT-proBNP ≥1200 pg/mL or BNP ≥375 pg/mL).
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Key exclusion criteria included: current haemodynamic or clinical insta-
bility requiring mechanical or intravenous medication, systolic blood
pressure (SBP) <85 mmHg, estimated glomerular filtration rate (eGFR)
<20 mL/min/1.73 m2, recent acute coronary syndrome events or car-
diovascular procedures (including planned procedures), and other con-
ditions with reduced life expectancy <2 years or that would adversely
affect participation in the trial. A full description of the eligibility criteria
has been published.13
Participants were randomized 1:1 to oral administration of either
placebo or omecamtiv mecarbil twice daily (pharmacokinetic-guided
dosing: 25, 37.5, or 50 mg bid). The primary objective of the
GALACTIC-HF trial is to determine in patients with HFrEF on
standard of care heart failure therapy whether omecamtiv mecarbil is
superior to placebo in reducing cardiovascular death or heart failure
events. A heart failure event is defined as an urgent, unscheduled
clinic/office/emergency department visit or hospital admission with a
primary diagnosis of heart failure where the patient exhibited new or
worsening symptoms of heart failure on presentation, had objective
evidence of new or worsening heart failure, and received initiation or
intensification of treatment specifically for heart failure. Additional sec-
ondary and exploratory outcomes have been published.13 The study
is endpoint-driven and will end after accumulation of approximately
1590 cardiovascular deaths.
Comparator studies
Three recent registries [European Society of Cardiology Heart Fail-
ure Long-Term Registry (ESC HF Long-Term Registry),14 Asian Sudden
Cardiac Death in Heart Failure (ASIAN-HF) registry,15,16 Change the
Management of Patients with Heart Failure (CHAMP-HF) registry17,18]
from varied international regions were reviewed to provide ‘real-world’
context for the GALACTIC-HF population. Moreover, patient charac-
teristics from four contemporary Phase III clinical trials of heart failure
pharmacologic therapies [Prospective comparison of ARNi with ACEi
to Determine Impact on Global Mortality and morbidity in Heart Fail-
ure (PARADIGM-HF),19 Dapagliflozin And Prevention of Adverse out-
comes in Heart Failure (DAPA-HF),20 Vericiguat global study in subjects
with heart failure with reduced ejection fraction (VICTORIA)21 and
Empagliflozin Outcome Trial in Patients with Chronic Heart Failure and
a Reduced Ejection Fraction (EMPEROR-Reduced)22] were compared
to those in GALACTIC-HF. GALACTIC-HF was designed to enrol
patients with HFrEF from both the inpatient and outpatient settings.
While many Phase III trials have been conducted to evaluate new intra-
venous therapies for patients with acute heart failure, three major trials
[Efficacy of Vasopressin Antagonism In Heart Failure Outcome Study
with Tolvaptan (EVEREST),23,24 Aliskiren Trial on Acute Heart Failure
Outcomes (ASTRONAUT),25 and Comparison of Sacubitril-Valsartan
vs. Enalapril on Effect on NT-proBNP in Patients Stabilized from an
Acute Heart Failure Episode (PIONEER-HF)26] have enrolled patients
stabilized during an admission for heart failure and treated with chronic
oral therapies. These trials have been used to provide the context for
GALACTIC-HF participants enrolled as inpatients.
Results
GALACTIC-HF baseline characteristics
Nearly 11 000 people were screened for enrolment in
GALACTIC-HF and approximately 25% did not meet eligibility



















































































.. 9 July 2019, 8256 participants were randomized at 945 sites in
35 countries. The baseline characteristics of these participants
are presented in Table 1 and in Figure 1. The participants were
on average 65 years of age, 21% female, and 78% self-identified
white race recruited from a wide range of regions (33% Eastern
Europe/Russia; 23% Western Europe/South Africa/Australasia;
19% Latin and South America; 17% North America; 8% Asia).
Comorbidities were common in the participants, including 62%
with coronary artery disease, 42% history of atrial fibrilla-
tion/flutter, 70% hypertension, and 40% diabetes mellitus. The
median (Q1–Q3) eGFR was 59 (44–74) mL/min/1.73 m2 and 52%
had chronic kidney disease stage III–V. The mean left ventricular
ejection fraction was 27%, predominantly due to an ischaemic aeti-
ology (54%). Participants had mild–moderate symptom limitation,
with 53% patients in NYHA functional class II and 47% in NYHA
functional class III/IV. The mean Kansas City Cardiomyopathy
Questionnaire total symptom score (KCCQ-TSS) was 66 (where
100 is the least symptom burden). Mean (standard deviation)
SBP was 117 (15) mmHg and the mean heart rate was 72 (12)
bpm. NT-proBNP was substantially elevated [median (Q1–Q3):
1971 (961–4033) pg/mL], with modestly elevated high-sensitivity
troponin I [median (Q3): 0.030 (0.049) ng/mL; upper limit
of 95% confidence interval: 0.014 ng/mL]. Patients were well
treated with guideline-recommended heart failure therapies at
baseline with 87% receiving an angiotensin-converting enzyme
inhibitor (ACEi)/angiotensin receptor blocker (ARB)/angiotensin
receptor–neprilysin inhibitor (ARNi) (19.3% ARNi), 94%
beta-blocker, and 77% mineralocorticoid receptor antagonist
(MRA). Approximately two-thirds of the participants were receiv-
ing triple therapy (ACEi/ARB/ARNi + beta-blocker + MRA).
Almost 32% of the patients had an implantable cardioverter defib-
rillator and 14% had cardiac resynchronization therapy at baseline.
Participants in GALACTIC-HF were enrolled from both the
inpatient and outpatient clinical settings. Of the 8256 participants,
2084 (25.2%) were enrolled as inpatients after stabilization during
a hospitalization for heart failure with a greater percentage of the
inpatient cohort enrolled in Eastern Europe and Russia (Table 1). As
might be anticipated, the participants enrolled during a heart failure
hospitalization also had a higher prevalence of chronic kidney dis-
ease and history of atrial fibrillation/flutter, had more symptomatic
heart failure (worse baseline NYHA functional class, MAGGIC
score, and KCCQ total symptom score), lower SBP and eGFR, and
higher NT-proBNP and high sensitivity troponin I concentrations
compared to those enrolled as outpatients. Although the use of
heart failure therapy was lower at baseline in the participants
enrolled as inpatients, 83% were treated with ACEi/ARB/ARNi
(16% ARNi), 93% with beta-blockers, 81% with MRA and 65%
with triple therapy [(ACEi/ARB/ARNi)+ beta-blocker + MRA].
The absence of adverse effects on renal function and blood
pressure in prior studies with omecamtiv mecarbil permitted
enrolment of patients in GALACTIC-HF with eGFR and SBP
lower than levels often excluded from HFrEF clinical trials.
Over 500 patients with eGFR <30 mL/min/1.73 m2 participated
(Table 2) and there were over 1100 participants in GALACTIC-HF
with SBP <100 mmHg (Table 2). GALACTIC-HF will provide
important insights into these two groups of patients that
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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(‘Inpatient’) (n = 2084)
Recent HF hospitalization
or ED visit within 1 year
(‘Outpatient’) (n = 6172)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Demographics
Age (years), mean (SD) 64.5 (11.3) 65.0 (11.3) 64.4 (11.4)
Female sex, n (%) 1756 (21.3) 411 (19.7) 1345 (21.8)
Race, n (%)
White 6421 (77.8) 1706 (81.9) 4715 (76.4)
Asian 710 (8.6) 184 (8.8) 526 (8.5)
Black or African American 562 (6.8) 105 (5.0) 457 (7.4)
Othera 563 (6.8) 89 (4.3) 474 (7.7)
Ethnicity, Hispanic/Latino, n (%) 1771 (21.5) 355 (17.0) 1416 (22.9)
Geographic region, n (%)
Eastern Europe/Russia 2705 (32.8) 915 (43.9) 1790 (29.0)
Western Europe/South Africa/Australasia 1921 (23.3) 486 (23.3) 1435 (23.3)
Latin and South America 1574 (19.1) 326 (15.6) 1248 (20.2)
US and Canada 1386 (16.8) 180 (8.6) 1206 (19.5)
Asia 670 (8.1) 177 (8.5) 493 (8.0)
Clinical characteristics
Medical conditions, n (%)
Coronary artery disease 5144 (62.3) 1317 (63.2) 3827 (62.0)
Myocardial infarction 3457 (41.9) 893 (42.9) 2564 (41.5)
Percutaneous coronary intervention 2452 (29.7) 599 (28.7) 1853 (30.0)
Coronary artery bypass grafting 1319 (16.0) 320 (15.4) 999 (16.2)
Peripheral artery disease 847 (10.3) 215 (10.3) 632 (10.2)
Stroke 753 (9.1) 197 (9.5) 556 (9.0)
Atrial fibrillation or flutter history 3472 (42.1) 995 (47.7) 2477 (40.1)
Hypertension 5800 (70.3) 1495 (71.7) 4305 (69.8)
Hypercholesterolaemia 4553 (55.1) 1094 (52.5) 3459 (56.0)
Type 2 diabetes mellitus 3313 (40.1) 870 (41.7) 2443 (39.6)
Chronic kidney disease 2977 (36.1) 809 (38.8) 2168 (35.1)
Chronic obstructive pulmonary disease 1344 (16.3) 354 (17.0) 990 (16.0)
Asthma 440 (5.3) 92 (4.4) 348 (5.6)
HF history
LVEF (%), mean (SD) 26.6 (6.3) 26.5 (6.4) 26.6 (6.2)
MAGGIC score, mean (SD) 23.3 (6.3) 25.0 (6.3) 22.8 (6.3)
NYHA class, n (%)
II 4391 (53.2) 767 (36.8) 3624 (58.7)
III 3616 (43.8) 1190 (57.1) 2426 (39.3)
IV 248 (3.0) 126 (6.0) 122 (2.0)
Ischaemic HF aetiology, n (%) 4458 (54.0) 1148 (55.1) 3310 (53.6)
KCCQ total symptom score, mean (SD) 66.4 (25.1) 52.6 (25.4) 71.0 (23.2)
Vitals and laboratory parameters
Body mass index (kg/m2), mean (SD) 28.5 (6.2) 28.0 (6.1) 28.6 (6.2)
SBP (mmHg), mean (SD) 117 (15) 114 (14) 117 (16)
Heart rate (bpm), mean (SD) 72 (12) 73 (12) 72 (12)
NT-proBNP (pg/mL), median (Q1–Q3) 1971 (961–4033) 2457 (1185–5073) 1858 (900–3749)
hsTnI (ng/mL), median (Q3) 0.030 (0.049) 0.036 (0.066) 0.029 (0.044)
eGFR (mL/min/1.73 m2), median (Q1–Q3) 59 (44–74) 54 (41–70) 60 (45–75)
Stage ≤2: >60 3922 (47.7) 838 (40.2) 3084 (50.0)
Stage 3: 30–59 3806 (46.1) 1077 (51.7) 2729 (44.2)
Stage 4: 15–29 523 (6.3) 169 (8.1) 354 (5.7)
Stage 5: <15 5 (<0.1) 0 (0.0) 5 (<0.1)
Medications and cardiac devices, n (%)
ACEi, ARB, or ARNi 7161 (86.7) 1729 (83.0) 5432 (88.0)
ARNi 1594 (19.3) 328 (15.7) 1266 (20.5)
BB 7763 (94.0) 1931 (92.7) 5832 (94.5)
MRA 6358 (77.0) 1686 (80.9) 4672 (75.7)
(ACEi, ARB, or ARNi)+MRA+BB 5367 (65.0) 1360 (65.3) 4007 (64.9)
Digitalis glycosides 1380 (16.7) 356 (17.1) 1024 (16.6)
SGLT2 inhibitors 219 (2.7) 56 (2.7) 163 (2.6)
Ivabradine 533 (6.5) 156 (7.5) 375 (6.1)
CRT 1156 (14.0) 267 (12.8) 889 (14.4)
ICD 2614 (31.7) 598 (28.7) 2016 (32.7)
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNi, angiotensin receptor–neprilysin inhibitor; BB, beta-blocker; CRT, cardiac resynchronization therapy; ED,
emergency department; eGFR, estimated glomerular filtration rate; HF, heart failure; hsTnI, high-sensitivity troponin I; ICD, implantable cardioverter defibrillator; KCCQ, Kansas City Cardiomyopathy
Questionnaire; LVEF, left ventricular ejection fraction; MAGGIC, Meta-Analysis Global Group in Chronic Heart Failure; MRA, mineralocorticoid receptor antagonist; NT-proBNP, N-terminal pro-B-type
natriuretic peptide; NYHA, New York Heart Association; SBP, systolic blood pressure; SD, standard deviation; SGLT2, sodium–glucose co-transporter 2.
Includes American Indian or Alaska native, native Hawaiian or other Pacific Islander, or multiple self-identified races.
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 Graphical representation of the GALACTIC-HF trial design, enrolment and baseline characteristics. ACEi, angiotensin-converting
enzyme inhibitor; ARB, angiotensin receptor blocker; ARNi, angiotensin receptor-neprilysin inhibitor; CRT, cardiac resynchronization therapy
(biventricular pacemaker); CV, cardiovascular; EF, ejection fraction; HFrEF, heart failure with reduced ejection fraction; ICD, implantable
cardioverter defibrillator; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, Hew York Heart Association; SBP, systolic blood
pressure.
have been underrepresented in other contemporary clinical
trials.
Comparison of GALACTIC-HF baseline
characteristics to other heart failure
populations
The baseline characteristics of participants in GALACTIC-HF
are compared to the population of patients in a number of
registries (online supplementary Table S2) as well as four major
contemporary trials (PARADIGM-HF, DAPA-HF, VICTORIA and
EMPEROR-Reduced) of pharmacologic therapies in participants
enrolled as outpatients with HFrEF (Table 3). To provide context
for GALACTIC-HF participants enrolled in-hospital, their baseline
characteristics were compared to patients from the EVEREST,
ASTRONAUT, and PIONEER-HF trials (Table 4). The key selection





























The GALACTIC-HF trial was designed to provide a comprehen-
sive assessment of the effect of chronic therapy with the cardiac
myosin activator omecamtiv mecarbil on cardiovascular mortality,
heart failure hospitalizations and quality of life in people with
HFrEF. Participants in GALACTIC-HF were randomized from a
diverse international population representing a wide spectrum of
the HFrEF clinical course. Their clinical characteristics are similar
to those of patients in contemporary registries (online supple-
mentary Table S2), although GALACTIC-HF patients tended to
be more symptomatic and received more guideline-recommended
medical therapy.
GALACTIC-HF randomized patients with many similarities to
those in other chronic heart failure trials (Table 3), though there
are some interesting differences, some of which were generated
by differences in the eligibility criteria (online supplementary
Table S3). The mean ages of patients in these contemporary HFrEF
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 2 Selected subgroups in GALACTIC-HF
Renal function SBP
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Demographics
Age (years), mean (SD) 70.5 (8.8) 64.1 (11.4) 63.3 (11.9) 64.7 (11.3)
Female sex, n (%) 175 (33.1) 1581 (20.5) 248 (22.0) 1508 (21.2)
Race, n (%)
White 450 (85.2) 5971 (77.3) 789 (70.0) 5632 (79.0)
Asian 19 (3.6) 691 (8.9) 188 (16.7) 522 (7.3)
Black or African American 24 (4.5) 538 (7.0) 72 (6.4) 490 (6.9)
Othera 35 (6.6) 528 (6.8) 78 (6.9) 485 (6.8)
Geographic region, n (%)
Eastern Europe/Russia 139 (26.3) 2566 (33.2) 136 (12.1) 2569 (36.0)
Western Europe/South Africa/Australasia 196 (37.1) 1725 (22.3) 363 (32.2) 1558 (21.9)
Latin and South America 86 (16.3) 1488 (19.3) 214 (19.0) 1360 (19.1)
US and Canada 90 (17.0) 1296 (16.8) 237 (21.0) 1149 (16.1)
Asia 17 (3.2) 653 (8.4) 177 (15.7) 493 (6.9)
Clinical characteristics
Medical conditions, n (%)
Coronary artery disease 397 (75.2) 4747 (61.4) 627 (55.6) 4517 (63.4)
Myocardial infarction 282 (53.4) 3175 (41.1) 455 (40.4) 3002 (42.1)
Peripheral artery disease 88 (16.7) 759 (9.8) 99 (8.8) 748 (10.5)
Stroke 63 (11.9) 690 (8.9) 111 (9.8) 642 (9.0)
Atrial fibrillation or flutter history 282 (53.4) 3190 (41.3) 509 (45.2) 2963 (41.6)
Hypertension 403 (76.3) 5397 (69.8) 551 (48.9) 5249 (73.6)
Hyperlipidaemia 352 (66.7) 4201 (54.4) 568 (50.4) 3985 (55.9)
Type 2 diabetes mellitus 287 (54.4) 3026 (39.2) 404 (35.8) 2909 (40.8)
Chronic kidney disease 466 (88.3) 2511 (32.5) 407 (36.1) 2570 (36.0)
Chronic obstructive pulmonary disease 92 (17.4) 1252 (16.2) 152 (13.5) 1192 (16.7)
HF history
LVEF (%), mean (SD) 26.7 (6.2) 26.6 (6.3) 24.0 (6.2) 27.0 (6.2)
Ischaemic HF, n (%) 353 (66.9) 4105 (53.1) 542 (48.1) 3916 (54.9)
NYHA class, n (%)
II 210 (39.8) 4181 (54.1) 557 (49.4) 3834 (53.8)
III 295 (55.9) 3321 (43.0) 523 (46.4) 3093 (43.4)
IV 23 (4.4) 225 (2.9) 47 (4.2) 201 (2.8)
KCCQ total symptom score, mean (SD) 60.2 (26.7) 66.8 (25.0) 64.3 (26.0) 66.7 (25.0)
MAGGIC score, mean (SD) 30.4 (5.5) 22.9 (6.1) 26.1 (6.5) 22.9 (6.2)
Vitals and laboratory parameters
Body mass index (kg/m2), mean (SD) 28.7 (5.7) 28.5 (6.2) 26.28 (5.6) 28.81 (6.2)
SBP (mmHg), mean (SD) 114.4 (16.7) 116.6 (15.2) 92.6 (4.6) 120.2 (12.8)
Heart rate (bpm), mean (SD) 70.4 (11.5) 72.5 (12.2) 72.5 (12.2) 72.3 (12.1)
NT-proBNP (pg/mL), median (Q1–Q3) 4525.0 (2082.0–8435.0) 1885.0 (924.0–3768.0) 2927.0 (1466.5–5835.0) 1858.0 (903.0–3775.0)
hsTnI (ng/mL), median (Q3) 0.040 (0.075) 0.030 (0.048) 0.030 (0.052) 0.030 (0.049)
eGFR (mL/min/1.73 m2), median (Q1–Q3) 25.7 (23.1–28.0) 60.4 (47.3–75.4) 55.2 (40.7–70.6) 59.3 (44.7–74.4)
Stage ≤2: >60 – 3922 (50.8) 461 (40.9) 3461 (48.5)
Stage 3: 30–59 – 3806 (49.2) 561 (49.8) 3245 (45.5)
Stage 4: 15–29 523 (99.1) – 104 (9.2) 419 (5.9)
Stage 5: <15 5 (0.9) – 1 (<0.1) 4 (<0.1)
Medications and cardiac devices, n (%)
ACEi, ARB, or ARNi 379 (71.8) 6782 (87.8) 957 (84.9) 6204 (87.0)
ARNi 110 (20.8) 1484 (19.2) 344 (30.5) 1250 (17.5)
BB 480 (90.9) 7283 (94.2) 1030 (91.4) 6733 (94.4)
MRA 294 (55.7) 6064 (78.5) 893 (79.2) 5465 (76.7)
(ACEi, ARB, or ARNi)+MRA+BB 217 (41.1) 5150 (66.6) 711 (63.1) 4656 (65.3)
Digitalis glycosides 54 (10.2) 1326 (17.2) 223 (19.8) 1157 (16.2)
SGLT2 inhibitors 7 (1.3) 212 (2.7) 44 (3.9) 175 (2.5)
Ivabradine 40 (7.6) 493 (6.4) 79 (7.0) 454 (6.4)
CRT 130 (24.6) 1026 (13.3) 248 (22.0) 908 (12.7)
ICD 235 (44.5) 2379 (30.8) 502 (44.5) 2112 (29.6)
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNi, angiotensin receptor–neprilysin inhibitor; BB, beta-blocker; CRT, cardiac resynchronization therapy; eGFR,
estimated glomerular filtration rate; HF, heart failure; hsTnI, high-sensitivity troponin I; ICD, implantable cardioverter defibrillator; KCCQ, Kansas City Cardiomyopathy Questionnaire; LVEF, left ventricular
ejection fraction; MAGGIC, Meta-Analysis Global Group in Chronic Heart Failure; MRA, mineralocorticoid receptor antagonist; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York
Heart Association; SBP, systolic blood pressure; SD, standard deviation; SGLT2, sodium–glucose co-transporter 2.
Includes American Indian or Alaska native, native Hawaiian or other Pacific Islander, or multiple self-identified races.
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Demographics
Age (years), mean (SD) 64.5 (11.3) 66.9 (11.0) 67.3 (12.2) 66.4 (11) 63.8 (11.4)
Female sex, n (%) 1756 (21.3) 893 (23.9) 1208 (23.9) 1109 (23.4) 1832 (22.0)
Race, n (%)
White 6421 (77.8) 2629 (70.5) 3239 (64.2) 3333 (70.3) 5544 (65.7)
Asian 710 (8.6) 672 (18.0) 1132 (22.4) 1116 (23.5) 1509 (17.9)
Black or African American 562 (6.8) 257 (6.9) 249 (4.9) 226 (4.8) 428 (5.1)
Geographic region, n (%)
Eastern Europe/Russia 2705 (32.8) All Europe 1353 (36.3) 1694 (33.5) 1604 (33.8) 2826 (33.5)
Western Europe/South Africa/Australasia 1921 (23.3) 889 (17.6) 550 (11.6) 2051 (24.3)
Latin and South America 1574 (19.1) 1286 (34.5) 724 (14.3) 817 (17.2) 1433 (17.0)
US and Canada 1386 (16.8) 425 (11.4) 560 (11.1) 677 (14.3) 602 (7.1)
Asia Pacific 670 (8.1) 493 (13.2) 1183 (23.4) 1069 (23.1) 1487 (17.6)
Index event, n (%)
Inpatient for HF 2084 (25.2) N/A a N/A N/A
HF hospitalization within 3 months 2992 (36.2) 3366 (66.7) 368 (7.8) 1611 (19.1)
IV diuretic for HF within 3 months (no hospitalization) N/A 813 (16.1) N/A N/A
HF hospitalization 3–6 months 1523 (18.4) 871 (17.2) 410 (8.6) 1009 (12.0)
HF hospitalization >6 months 1636 (19.8) N/A 1473 (31.0) 2632 (31.2)
Clinical characteristics
Medical conditions, n (%)
Coronary artery disease 5144 (62.3) 1710 (45.8) 2944 (58.3) – 4796 (57.1)
Myocardial infarction 3457 (41.9) 1623 (43.5) 1977 (44.5) 3634 (43.0)
Peripheral artery disease 847 (10.3) 261 (7.0) 630 (12.5) 324 (6.8)
Stroke 753 (9.1) 421 (11.3) 578 (11.5) 472 (9.9) 725 (8.7)
Atrial fibrillation or flutter history 3472 (42.1) 1369 (36.7) 2268 (44.9) 1818 (38.3) 3091 (37.0)
Hypertension 5800 (70.3) 2698 (72.3) 3995 (79.1) (74) 5940 (71.2)
Type 2 diabetes mellitus 3313 (40.1) 1856 (49.8) 2369 (46.9) 1983 (41.8) 2907 (34.9)
Chronic obstructive pulmonary disease 1344 (16.3) 443 (11.9) 867 (17.2) 585 (12.3) 1080 (12.9)
HF history
LVEF (%), mean (SD) 26.6 (6.3) 27.5 (6.1) 28.9 (8.3) 31.1 (6.8) 29.5 (6.2)
Ischaemic HF aetiology, n (%) 4458 (54.0) 1929 (51.7) 2674 (56.4) 5036 (59.7)
NYHA class, n (%)
I 0 0 2 (0.0) 0 389 (4.7)
II 4391 (53.2) 2800 (75.1) 2975 (59.0) 3203 (67.5) 5919 (70.9)
III 3616 (43.8) 910 (24.4) 2003 (39.7) 1498 (31.6) 2018 (24.1)
IV 248 (3.0) 20 (0.5) 66 (1.3) 43 (0.9) 60 (0.7)
KCCQ total symptom score, median (Q1–Q3) 68.8 (49.0–87.5) 77.1 (58.3–91.7) 83.3 (67.7–95.8)
MAGGIC score, median (Q1– Q3) 23 (19–28) 23 (18–27) 22 (18, 25) 20 (16–24)
Vitals and laboratory parameters
Body mass index (kg/m2), mean (SD) 28.5 (6.2) 27.9 (5.4) 27.8 (5.9) 28.2 (6.0) 28.2 (5.5)
SBP (mmHg), mean (SD) 117 (15) 122 (15) 121 (16) 122 (16) 121 (15)
Heart rate (bpm), mean (SD) 72.4 (12.1) 71.3 (11.8) 73.1 (13.0) 71.5 (11.7) 72 (12)
NT-proBNP (pg/mL), median (Q1–Q3) 1971 (962–4033) E: 1887 (1077–3429)
P: 1926 (1153–3525)
2816 (1556–5314) 1437 (857–2649) 1608 (886–3221)
eGFR (mL/min/1.73 m2), mean (SD) 60.3 (21.8) 62.0 (21.6) 61.5 (27.2) 65.8 (19.4) 70 (20)
Stage ≤2: ≥60 3922 (47.5) 1929 (51.7) 2335 (47.1) 2782 (58.6) 5654 (67.0)
Stage ≥3: <60 4334 (52.5) 1799 (48.3) 2624 (52.0) 1962 (40.2) 2745 (33.0)
Medications and cardiac devices, n (%)
ACEi, ARB, or ARNi 7161 (86.7) 3327 (89.2) 3700 (73.4) 4476 (94.4) 8339 (100)
ARNi 1594 (19.3) 727 (19.5) 731 (14.5) 508 (10.7) N/A
BB 7763 (94.0) 3533 (94.7) 4691 (93.1) 4558 (96.1) 7811 (93.6)
MRA 6358 (77.0) 2661 (71.3) 3545 (70.3) 3370 (71.0) 4671 (55.3)
(ACEi, ARB, or ARNi)+MRA+BB 5367 (65.0) 3009 (59.7) 3097 (65.3) (≤55.3)
Digitalis glycosides 1380 (16.7) 594 (15.9) 887 (18.7) 2539 (30.2)
ICD 2614 (31.7) 1171 (31.4) 1399 (27.8) 1242 (26.2) 1243 (14.9)
CRT 1156 (14.0) 442 (11.8) 739 (14.7) 354 (7.5) 574 (6.8)
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNi, angiotensin receptor–neprilysin inhibitor; BB, beta-blocker; CRT, cardiac resynchronization therapy; E,
empagliflozin group; eGFR, estimated glomerular filtration rate; HF, heart failure; ICD, implantable cardioverter defibrillator; IV, intravenous; KCCQ, Kansas City Cardiomyopathy Questionnaire; LVEF,
left ventricular ejection fraction; MAGGIC, Meta-Analysis Global Group in Chronic Heart Failure; MRA, mineralocorticoid receptor antagonist; N/A, not available; NT-proBNP, N-terminal pro-B-type
natriuretic peptide; NYHA, New York Heart Association; P, placebo group; SBP, systolic blood pressure; SD, standard deviation.
aVICTORIA also enrolled inpatients, although these data were not available at this time.
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 4 Baseline characteristics and treatment in stabilized inpatients in contemporary trials
GALACTIC-HF
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Demographics
Age (years), mean (SD) or median (Q1–Q3) 65.0 (11.3) 65.8 (11.8) 64.6 (12.2) 62 (53–71)
Female sex, n (%) 411 (19.7) 25.6 368 (22.7) 246 (27.9)
Race, n (%)
White 1706 (81.9) 3533 (85.5) 1140 (70.6) 515 (58.5)
Asian 184 (8.8) N/A 336 (20.8)
Black or African American 105 (5.0) 310 (7.5) 78 (4.8) 316 (35.9)
Otherb 89 (4.3) 290 (7.0) 61 (3.8) 50 (5.7)
Hispanic ethnicity, n (%) 355 (17.0) 201 (4.9) 75 (8.5)
Geographic region, n (%)
Eastern Europe/Russia 915 (43.9%) 1619 (39.2) 498 (30.4) –
Western Europe/South Africa/Australasia 486 (23.3%) 564 (13.6) 407 (24.8) –
Latin and South America 326 (15.6%) 699 (16.9) 165 (10.1) –
US and Canada 180 (8.6%) 1251 (30.2) 124 (7.6) 881 (100)
Asia 177 (8.5%) – 445 (27.2) –
Clinical characteristics
Medical conditions, n (%)
Coronary artery disease 1317 (63.2) 2911 (70.4) 881 (54.6) 244 (27.7)
Myocardial infarction 893 (42.9) 2084 (50.4) 689 (42.7) 62 (7.0)
Percutaneous coronary intervention 599 (28.7) 738 (17.9) 323 (20.0) 8 (0.9)
Coronary artery bypass grafting 320 (15.4) 862 (20.9) 279 (17.3) 35 (4.0)
Peripheral artery disease 215 (10.3) 866 (21.0) 95 (10.8)
Stroke 197 (9.5) 471 (11.4) 87 (9.9)
Atrial fibrillation or flutter history 995 (47.7) 1790 (43.3) 676 (41.9) 407 (46.2)
Hypertension 1495 (71.7) 2932 (70.9) 1225 (75.9) 753 (85.6)
Type 2 diabetes mellitus 870 (41.7) 1598 (38.7) 662 (41.0) 168 (19.1)
Chronic kidney disease 809 (38.8) 1107 (26.8) 332 (20.6) 250 (29.1)
Chronic obstructive pulmonary disease 354 (17.0) 416 (10.1) 322 (19.9)
HF history
LVEF (%), mean (SD) or median (Q1–Q3) 26.5 (6.4) 27.5 (8.1) 27.9 (7.3) 25 (20–30)
Ischaemic HF aetiology, n (%) 1148 (55.1) 2672 (64.6) 1027 (63.6)
NYHA class at randomization, n (%)
II 767 (36.8) 513 (31.8) 112 (19.4)
III 1190 (57.1) 2404 (59.4) 903 (55.9) 297 (51.6)
IV 126 (6.0) 1622 (40.1) 139 (8.6) 54 (9.4)
Vitals and laboratory parameters
Body mass index (kg/m2), mean (SD) or median (Q1, Q3) 28.0 (6.1) 27.2 (6.2) 30 (26–37)
SBP (mmHg), mean (SD) or median (Q1, Q3) 114 (14) 121 (19) 123 (13) 118 (110–132)
Heart rate (bpm), mean (SD) or median (Q1, Q3) 73 (12) 80 78 (16) 80 (72–91)
NT-proBNP (pg/mL), median (Q1–Q3) at randomization 2457 (1185–5073) 2718 (1531–5235) 2701 (1490–5218)
hsTnI (ng/mL), median (Q3) 0.036 (0.066) 0.035 (0.08) 0.032 (0.050)
eGFR (mL/min/1.73 m2), mean (SD) or median (Q1–Q3) 54.4 (41.3–70.2) 66.7 (19.9) 59 (48–71)
Medications and cardiac devices, n (%)
ACEi, ARB, or ARNi 1729 (83.0) 3479 (84.2) 1360 (84.2) 422 (47.9)a
BB 1931 (92.7) 2903 (70.2) 1333 (82.5) 525 (59.6)
MRA 1686 (80.9) 2242 (54.2) 921 (57.0) 88 (10.0)
(ACEi, ARB, or ARNi)+MRA+BB 1360 (65.3) (≤54.2) (≤57.0) 502 (57.0)a
Digitalis glycosides 356 (17.1) 1815 (43.9) 628 (38.9) 76 (8.6)
CRT 267 (12.8) 109 (6.7) 76 (8.6)
ICD 598 (28.7) 600 (14.5) 253 (15.7) 250 (28.3)
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNi, angiotensin receptor–neprilysin inhibitor; BB, beta-blocker; CRT, cardiac
resynchronization therapy; eGFR, estimated glomerular filtration rate; HF, heart failure; hsTnI, high-sensitivity troponin I; ICD, implantable cardioverter defibrillator; MRA,
mineralocorticoid receptor antagonist; N/A, not available; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; SBP, systolic blood
pressure; SD, standard deviation.
aNote that PIONEER-HF enrolled de novo HF patients and patients on ARNi were excluded, so this value represents patients on ACEi or ARB at baseline.
bIncludes American Indian or Alaska native, native Hawaiian or other Pacific Islander, or multiple self-identified races.
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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trials ranged from 64–67 years and 21–24% of the participants
were females. Racial characteristics differed amongst the trials,
with GALACTIC-HF enrolling a high percentage of self-identified
Black participants (6.8%) compared to the other trials (4.8–6.9%),
but a substantially lower proportion of Asian patients (8.6% vs.
17.9–23.5%). These proportions reflect the geographic distribu-
tion of recruitment, where GALACTIC-HF enrolled more patients
from the United States and Canada (16.8% vs. 7.1–14.3%), but
fewer participants from Asia (8.1% vs. 13.2–23.4%). Given the size
of GALACTIC-HF, these proportions translated into substantially
greater absolute numbers of patients (nearly twice as many as
the comparators) in North America where recruitment has been
historically challenging. Comorbidities were common and similar
in all of the trials with a history of atrial fibrillation present in about
37–45%, type 2 diabetes mellitus in 35–50% and hypertension
in 70–79% of subjects. The participants in GALACTIC-HF had
a slightly lower ejection fraction than the other trials (26.6% vs.
27.5–31.1%) and higher NT-proBNP concentrations compared
to PARADIGM-HF, DAPA-HF and EMPEROR-Reduced, the latter
being potentially related to enrolling inpatients. As opposed to
the other trials which enrolled patients with predominantly mild
symptoms (59–75% NYHA class II), patients with a broader
range of symptoms are represented in GALACTIC-HF from mild
(NYHA class II, 53%) to moderate–severe (NYHA class III/IV,
47%) symptoms.
The GALACTIC-HF cohort is a unique population, comprising
patients enrolled from both the inpatient and outpatient settings.
For comparison, the VICTORIA trial21 specifically randomized
patients (n = 3366; 66.7%) in the high-risk period within 3 months
of hospitalization for heart failure. GALACTIC-HF also has a
robust representation of these high-risk patients (n = 4976;
60.3%). In the Phase 2 trial of omecamtiv mecarbil in patients with
acute heart failure, ATOMIC-AHF,6 606 patients were randomized
to a 48 h infusion of placebo or omecamtiv mecarbil in ascending
dose cohorts. In these acutely ill inpatients, omecamtiv mecarbil
had a side-effect profile similar to placebo and improved dyspnoea
in the high-dose group. In the context of these safety data and with
the recognition that early initiation of disease-modifying therapies
would optimize medication adherence and its potential benefit,
GALACTIC-HF randomized 2084 patients (25.2%) in the inpatient
setting. A greater proportion of subjects enrolled as inpatients
had a history of atrial fibrillation/flutter and chronic renal disease
compared to the outpatient cohort. While this inpatient group had
the same left ventricular ejection fraction as those randomized as
outpatients, the inpatients were more symptomatic as represented
by worse NYHA functional class and KCCQ total symptom scores
and also had lower blood pressure, worse renal function, and
higher NT-proBNP and troponin I concentrations. Three other
large multicentre trials have enrolled stabilized inpatients with
HFrEF who were hospitalized for acute heart failure (Table 4; online
supplementary Table S3). The international trials EVEREST23,24 and
ASTRONAUT25 enrolled patients with a history of HFrEF who
had baseline characteristics similar to the inpatient group from
GALACTIC-HF, except for the worse renal function and lower
SBP in GALACTIC-HF. The lower heart rate in GALACTIC-HF



















































































.. use of beta-blockers at baseline. PIONEER-HF26 also enrolled
patients who were haemodynamically stable while hospitalized
for acute decompensated heart failure but only in the United
States. PIONEER-HF had a higher representation of women and
Blacks compared to the other three trials, as well as higher
prevalence of obesity and hypertension. Patients in PIONEER-HF
had a much lower use of renin–angiotensin system inhibitors (48%
ACEi/ARB vs. 83% ACEi/ARB/ARNi), beta-blockers (60% vs. 94%)
and MRA (10% vs. 81%) compared to the inpatient group from
GALACTIC-HF, although PIONEER-HF randomized patients with
de novo heart failure such that only 65.4% of patients had a prior
history of heart failure.
Adverse effects on renal function are a major impediment to
the initiation, up-titration and maintenance of many current heart
failure therapies. Omecamtiv mecarbil has demonstrated no sig-
nificant difference from placebo with respect to renal function or
related adverse events in Phase I or II clinical studies. Consequently,
the entry criterion for renal function in GALACTIC-HF was
among the lowest of any contemporary clinical trial, enrolling
patients with an eGFR ≥20 mL/min/1.73 m2 who were not
on dialysis. GALACTIC-HF enrolled 528 patients with eGFR
<30 mL/min/1.73 m2, representing 6.4% of total enrolment. These
patients are a distinct group with a greater proportion being
women and older age, enrolled as inpatients with lower SBP, more
comorbidities and ischaemic aetiology of heart failure, more symp-
tomatic heart failure (worse NYHA class, MAGGIC and KCCQ
total symptom scores) and markedly higher NT-proBNP, increased
troponin, on less guideline-recommended medical therapy, yet a
greater proportion of device therapy, compared to those with
better renal function. Patients with an eGFR ≥20 mL/min/1.73 m2
were also enrolled in EMPEROR-Reduced. These patients are
typically a poorly studied group in HFrEF therapeutic trials
and were excluded from ASTRONAUT,25 PARADIGM-HF,19
PIONEER-HF26 and DAPA-HF.27 In the VICTORIA trial21 of the
soluble guanylate cyclase activator vericiguat, patients with an
eGFR ≥15 mL/min/1.73 m2 were enrolled and there were 506
patients enrolled with an eGFR ≤30 mL/min/1.73 m2 (10.2% of
total enrolment).
Many patients with HFrEF have lower blood pressure, espe-
cially those on maximal neurohormonal antagonist therapy, yet
due to the hypotensive effects of many investigational therapies,
these patients have been excluded from contemporary clinical
trials. Trials with aliskiren (ASTRONAUT,23,24 SBP <110 mmHg),
sacubitril/valsartan (PARADIGM-HF,19 PIONEER-HF26), vericiguat
(VICTORIA21) and empagliflozin (EMPEROR-Reduced22) excluded
patients with SBP <100 mmHg, while DAPA-HF27 (dapagliflozin)
excluded those with SBP <95 mmHg. Omecamtiv mecarbil has no
vasodilating properties and does not adversely affect blood pres-
sure, so the GALACTIC-HF trial was able to study patients with
SBP ≥85 mmHg, randomizing 1127 patients (13.7%) with a base-
line SBP <100 mmHg. These patients were slightly younger and
more frequently enrolled as inpatients, with lower left ventricu-
lar ejection fraction, mildly increased NT-proBNP and troponin,
decreased eGFR, fewer with ischaemic aetiology of heart failure,
and more symptomatic heart failure (worse NYHA class, MAG-
GIC and KCCQ total symptom scores), compared to participants
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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with higher SBP. GALACTIC-HF provides a unique opportunity
to prospectively evaluate a therapy in this large, but underserved
group of patients with HFrEF.
Comprehensive background heart failure therapy is not only
important for the appropriate care of the participants but is also
essential to the evaluation of the additional therapeutic benefit
of a study drug. Patients in GALACTIC-HF received amongst the
most comprehensive baseline heart failure therapy in contem-
porary clinical trials. Implantable cardioverter defibrillators were
in 32% (15–31% in PARADIGM-HF, DAPA-HF, VICTORIA, and
EMPEROR-Reduced) and cardiac resynchronization therapy was
present in 14% of patients in GALACTIC-HF at baseline (7–15%
in the other four trials). In terms of baseline medical therapies
employed, 87% of participants in GALACTIC-HF received an
ACEi, ARB or ARNi, compared to 73–94% in PARADIGM-HF,
DAPA-HF, VICTORIA, and EMPEROR-Reduced. Beta-blockers
were administered to 94% of patients in GALACTIC-HF, similar
to the 93–96% of patients in the other trials. MRA administration
was more common in GALACTIC-HF (77% compared to 55–71%
in the other trials). The absence of adverse effects of omecamtiv
mecarbil on potassium homeostasis may have accounted for the
investigators’ comfort in enrolling patients with the highest per-
centage of MRA use in any contemporary clinical trial. Unlike the
PARADIGM-HF, PIONEER-HF, ASTRONAUT, and EVEREST trials,
GALACTIC-HF had no exclusion criterion for potassium plasma
concentrations. Triple therapy (ACEi/ARB/ARNi + beta-blocker
+ MRA) was present in 65% of the GALACTIC-HF patients
compared to less than 55% to 65% in the other three contem-
porary trials. Relative to DAPA-HF (n = 508, 11%), VICTORIA
(n = 731, 14%) and EMPEROR-Reduced (n = 727; 19.5%), almost
1600 patients (over 19%) in GALACTIC-HF were treated with
sacubitril/valsartan at baseline. As might be expected given the
different timing of regulatory approvals and accessibility of sacubi-
tril/valsartan worldwide, there was considerable regional variation
in baseline ARNi use, ranging from approximately 5% of patients in
Eastern Europe to almost one-third of patients in North America
and Western Europe.
A recent study demonstrated that failure to initiate or up-titrate
guideline-recommended medical therapies to target doses is most
frequently due to physiologic factors, such as blood pressure,
heart rate, renal function, or potassium concentrations rather than
physician inertia.28 In Phase I and II clinical studies of omecamtiv
mecarbil, there was no adverse effect on blood pressure, heart
rate, renal function, or potassium homeostasis. These findings
suggest that omecamtiv mecarbil should not interfere with baseline
guideline-recommended medical therapy and has the potential
to facilitate initiation or up-titration of these therapies through
improved cardiac function.
Limitations
GALACTIC-HF is one of the most inclusive contemporary clinical
trials, but there are some important limitations. Underrepresen-
tation of racial groups and women in clinical trials is a continu-
ing concern.29 Only 7% of the GALACTIC-HF participants were



















































































.. representing over 100 more Black patients than were random-
ized in PARADIGM-HF and over twice that enrolled in VIC-
TORIA (n = 249), DAPA-HF (n = 226) or EMPEROR-Reduced
(n = 257). Moreover, in the United States, over 29% of the
GALACTIC-HF participants self-reported race as Black, more than
twice the corresponding proportion of U.S. population (13.4%).
Asian, Pacific Islander and other non-white racial groups have
limited representation in this trial. In addition, women continue
to constitute a minority of patients with HFrEF in both reg-
istries and clinical trials.30 Approximately 21% of the participants
in GALACTIC-HF were female, constituting a database of over
1700 women with HFrEF in whom the effects of omecamtiv mecar-
bil can be evaluated. The recent compelling trial results from
DAPA-HF27 and EMPEROR-Reduced22 have established a role for
the sodium–glucose co-transporter 2 (SGLT2) inhibitors in the
treatment of patients with HFrEF, but these data did not enter clini-
cal practice or guidelines until after GALACTIC-HF had completed
enrolment. Only 219 (2.7%) patients in GALACTIC-HF were on
SGLT2 inhibitors at baseline, but given that the mechanism of action
of the cardiac myosin activator omecamtiv mecarbil has no appar-
ent significant overlap with that of the SGLT2 inhibitors, there is
minimal biological plausibility that they would interfere with the
other’s effects on clinical outcomes, and there is the suggestion
that they could be complementary or even synergistic.
Conclusion
GALACTIC-HF is the first trial to test the hypothesis that directly
improving cardiac function with the novel, selective cardiac myosin
activator omecamtiv mecarbil can safely improve symptoms, pre-
vent clinical heart failure events, and reduce the risk of cardiovas-
cular death in patients with HFrEF. To this end, the trial enrolled
patients with a wide range of symptomatic HFrEF receiving excel-
lent medical and device heart failure therapy who were simi-
lar to those enrolled in other contemporary heart failure trials
and registries. GALACTIC-HF also randomized patients typically
excluded from chronic heart failure trials including inpatients and
those with severely reduced renal function or low blood pressure.
GALACTIC-HF will provide a definitive evaluation of the efficacy
and safety of this novel therapy, and, if effective, inform its future
implementation.
Supplementary Information
Additional supporting information may be found online in the
Supporting Information section at the end of the article.
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